The company that markets LEVAQUIN in the U.S.,
presented the data during a scientific session that a short course of five
LEVAQUIN (levofloxacin) 750 mg tablets
administered once-daily for five days is as effective as standard therapy
urinary tract infections and acute pyelonephritis.
LEVAQUIN is available in 250
mg, 500 mg and 750 mg doses in both oral and I.V. formulations.
Since its introduction in 1996, LEVAQUIN has gained widespread use
in the treatment for a variety of bacterial infections caused by
susceptible pathogens, such us chronic bacterial prostatitis, urinary tract infections
and acute pyelonephritis (mild to moderate) acute bacterial sinusitis, nosocomial pneumonia, acute
bacterial exacerbation of chronic bronchitis, community-acquired pneumonia, complicated and uncomplicated skin and skin
structure infections .